Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical, Immunological, and Molecular Features of Severe Combined Immune Deficiency: A Multi-Institutional Experience From India.
Vignesh P, Rawat A, Kumrah R, Singh A, Gummadi A, Sharma M, Kaur A, Nameirakpam J, Jindal A, Suri D, Gupta A, Khadwal A, Saikia B, Minz RW, Sharma K, Desai M, Taur P, Gowri V, Pandrowala A, Dalvi A, Jodhawat N, Kambli P, Madkaikar MR, Bhattad S, Ramprakash S, Cp R, Jayaram A, Sivasankaran M, Munirathnam D, Balaji S, Rajendran A, Aggarwal A, Singh K, Na F, George B, Mehta A, Lashkari HP, Uppuluri R, Raj R, Bartakke S, Gupta K, Sreedharanunni S, Ogura Y, Kato T, Imai K, Chan KW, Leung D, Ohara O, Nonoyama S, Hershfield M, Lau YL, Singh S. Vignesh P, et al. Among authors: sreedharanunni s. Front Immunol. 2021 Feb 8;11:619146. doi: 10.3389/fimmu.2020.619146. eCollection 2020. Front Immunol. 2021. PMID: 33628209 Free PMC article.
Modified CLL International Prognostic Index (CLL-LIPI) using lymphocyte doubling time (LDT) in place of IgHV mutation status in resource-limited settings predicts time to first treatment and overall survival.
Lad DP, Tejaswi V, Jindal N, Malhotra P, Khadwal A, Prakash G, Jain A, Sreedharanunni S, Sachdeva MS, Naseem S, Varma N, Varma S. Lad DP, et al. Among authors: sreedharanunni s. Leuk Lymphoma. 2020 Jun;61(6):1512-1515. doi: 10.1080/10428194.2020.1719099. Epub 2020 Jan 29. Leuk Lymphoma. 2020. PMID: 31992098 No abstract available.
Chronic Lymphocytic Leukemia: Real-World Data From India.
Tejaswi V, Lad DP, Jindal N, Prakash G, Malhotra P, Khadwal A, Jain A, Sreedharanunni S, Sachdeva MS, Naseem S, Varma N, Varma S. Tejaswi V, et al. Among authors: sreedharanunni s. JCO Glob Oncol. 2020 Jun;6:866-872. doi: 10.1200/GO.20.00032. JCO Glob Oncol. 2020. PMID: 32579486 Free PMC article.
Randomized controlled trial of individualized, low dose, fixed duration lenalidomide maintenance versus observation after frontline chemo-immunotherapy in CLL.
Jindal N, Lad DP, Malhotra P, Prakash G, Khadwal A, Jain A, Sachdeva MS, Sreedharanunni S, Naseem S, Varma N, Varma S. Jindal N, et al. Among authors: sreedharanunni s. Leuk Lymphoma. 2021 Jul;62(7):1674-1681. doi: 10.1080/10428194.2021.1885668. Epub 2021 Feb 21. Leuk Lymphoma. 2021. PMID: 33612059 Clinical Trial.
114 results